Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
By D. Marin, A. Bazeos, F. Mahon, L. Eliasson, D. Milojkovic, M. Bua, J. Apperley, Richard Szydlo, R. Desai, K. Kozlowski and 10 more. Journal of Clinical Oncology, 2010
918 citations recorded by the source corpus.
Subfields: Family Practice, Hematology, Plant Science
View Paper: https://www.semanticscholar.org/paper/51e5e2cce6682c01b59bd7fa25ec76c89ce866a1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Plant Science
Citations in the corpus
- Self-report measures of medication adherence behavior: recommendations on optimal use (2015, background): “, 10–20 %) has been linked with clinically significant deteriorations in health outcomes, such as glycemic control, low-density lipoprotein cholesterol levels, and risk for coronary disease [21, 22], aswell as failure to achieve health improvements [23], leading to higher healthcare costs [21, 24].”
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, background): “compliance, which is a major cause of failure.(4,5,18,19,28-31,42,136-143) Many of these side effects are common to all TKIs, with some differences in frequency and severity, so that several patients can benefit from changing the TKI.”
- Chronic Myeloid Leukemia (2007, neutral): “korekcia parametrov vnútorného prostredia [19,20].”
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016, background): “AEs have been reported to increase nonadherence to TKIs.(42,43) The proportion of patients in DASISION who discontinued dasatinib or imatinib as a result of poor compliance or noncompliance was small.”